Neon Therapeutics announced the appointment of Richard Gaynor, M.D., to president of research and development. Dr. Gaynor succeeds interim chief scientific officer Robert Tepper, M.D., a partner at Third Rock Ventures, who is continuing as a member of the company’s board of directors. Dr. Gaynor recently retired from Eli Lilly’s oncology division, where he held the position of senior vice president of global product development and medical affairs since 2013.